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trait. 7 Thus, a PCP might be the first to contact the family; explain and educate the family on the positive results; and arrange genetic counseling, confirmatory testing, and referral to a hematologist. Although this role is important, up to 10% of pediatricians and one-third of family physicians do not feel competent discussing NBS test results. 8 Hence, knowledge not only of interpretation of NBS, but also basic knowledge of different hemoglobinopathies/thalassemias is essential for providing the patients with better quality of care.
This article gives a basic overview of different hemoglobinopathies/thalassemias, provides clues for identification of abnormal NBS patterns characteristic of different hemoglobinopathies/thalassemias, and discusses indications for follow-up evaluation as well as referral to hematologist and genetic counselor.
NORMAL HEMOGLOBIN DEVELOPMENT AND HEMOGLOBIN SWITCH
In order to better understand and interpret NBS results, an understanding of normal hemoglobin development and switch from fetal hemoglobin to adult hemoglobin is essential. Normal adult hemoglobin (HbA) is a tetramer of two α chains and two β chains (α 2 β 2 ). In humans, there are four α genes on chromosome 16 and two β loci on chromosome 11. During embryonic and fetal development, timed hemoglobin switch from embryonic to fetal and later to adult hemoglobin occurs. In the embryonic stage, ζ-and ε-globin chains are expressed before the γ globin and α globin chains. Between 4 and 14 weeks, three distinct Hbs are produced; ζ 2 , ε 2 (Hb Gower-1), ζ 2 γ 2 (Hb Portland), and α 2 ε 2 (Hb Gower-2). 9 After development of the placenta, embryonic hemoglobins are replaced by hemoglobin F (HbF) (α 2 γ 2 ). 9 At birth, fetal hemoglobin is the predominant hemoglobin ( Table 1) . Depending on the gestation age at birth, its value can range from about 70% in a term newborn to 95% in an extreme preterm newborn. The level of HbF decreases progressively during the first year of life, with a corresponding increase in adult hemoglobin (HbA). The normal adult level is reached by age 1 year. Hemoglobin A2 (HbA 2 ), a combination of α chain with δ chains (α 2 δ 2 ), is present both in the neonatal period and during the rest of an individual's life. A schematic illustration of hemoglobin switch is shown in Figure 1 .
INTRODUCTION TO HEMOGLOBINOPATHIES Sickle Cell Disease
SCD is a common hemoglobinopathy in the US. It is estimated that SCD occurs among 1 in every 500 African-American and 1 in every 36,000 Hispanic-American births. 10 Increased incidence of SCD is also noted in individuals of Mediterranean, Middle Eastern, Indian, Caribbean, and South and Central American ancestry. The sickle hemoglobin results from a point mutation (A-T) in the sixth codon of the β globin gene, which leads to amino acid substitution from glutamine to valine. Clinically, SCD is characterized by varying degrees of anemia, vaso-occulsive pain crisis, acute chest syndrome, stroke, splenic sequestration, priapism, and multiple end-organ damage. In infants, increased susceptibility to pneumococcal infection, dactilitis, and splenic sequestration are common. 9, 11 The clinical severity of SCD depends on the genotype of SCD and the associated disease modifiers ( Table 2) . HbSS and HbSβ 0 thalassemia are more severe than HbSβ + and HbSC disease. 9, 11 Coinheritance of defects in the α chain (found in approximately 35% of patients with SCD) results in decreased HbS levels, which leads to decreased disease severity. Early identification by NBS and initiation of penicillin prophylaxis, pneumococcal vaccination, parental education, and comprehensive care has dramatically decreased the early mortality in SCD.
Sickle Cell Trait Individuals with sickle cell trait (SCT) are generally asymptomatic and are expected to have normal life ex- 
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pectancy. 9, 11 However, certain clinical abnormalities have been identified in patients with SCT. Urine concentrating defect due to microscopic infarction of the renal medulla is one of the most common abnormalities found in SCT.
11
Hematuria from papillary necrosis of the kidney is also associated with SCT. 12 SCT was initially thought to be associated with a high incidence of sudden death on extreme physical exertion, 13 but follow-up studies showed that adequate hydration and training eliminates this risk.
14 Hence, SCT is not a contraindication to participate in competitive sports. Under certain extreme conditions of hypoxia, such as severe pneumonia and exercise at high altitudes, sickling may occur in individuals with SCT. These risk factors need to be highlighted at the time of counseling.
Non-Sickle Hemoglobin Abnormalities
The prevalence of non-sickle cell hemoglobin abnormalities (Table 3) , such as α and β thalassemias, is being increasingly recognized in the U.S. 5 With the increase in Asian immigration, especially from Southeast Asia and China, the prevalence of HbH disease and HbEβ thalassemia has increased compared with classic β thalassemia in parts of the U.S.
α Thalassemia syndrome
In the U.S., α thalassemia is commonly seen in infants of Southeast Asian and southern Chinese descent. 5 In humans, there are four α genes. Loss of one α gene (++/+-) results in a silent carrier state with no anemia or microcytosis. Loss of two α genes (Cis --/++ or Trans -+/-+) results in the α thalassemia trait characterized by mild anemia and microcytosis. Loss of three genes (--/-+) results in HbH disease, characterized by elevated HbH (β4), leading to hemolytic anemia of varying severity and transfusion requirement. Loss of all four α genes results in Hb Barts (γ4), which usually results in hydrops fetalis, leading to in utero death in most cases. HbHCS is caused by point mutation in the stop codon of the α chain mRNA, leading to a markedly long (α CS ) chain and a decreased α chain synthesis. When α CS occurs in the setting of cis α-chain defect, it behaves as HbH disease. 15 As illustrated in Table 3 , clinically significant α thalassemia defects are common in newborns of Southeast Asian and southern Chinese descent. Although African Americans also have high asymptomatic carrier frequency of α chain defects, they very rarely develop HbH disease. This is because most African Americans carry the α chain defect in the trans state (-+/-+) compared with the cis α-chain defect (--/++) seen in Southeast Asian and southern Chinese populations.
β Thalassemia β thalassemia is commonly reported in newborns of Asian Indian, Middle Eastern, and Southeast Asian descent. β thalassemia results from impaired production of β globin; the mutation in β globin could either result in total absence of β globin (β 0 ) or decreased β globin synthesis (β + ) resulting in some HbA formation. The clinical spectrum can vary from transfusion-independent β thalassemia intermedia phenotype to transfusion-dependent β thalassemia major phenotype. Individuals with the β thalassemia trait are asymptomatic, with mild microcytic hypochromic anemia, target cells, and characteristic HbA 2 elevation on electrophoresis.
Hemoglobin E disease
HbE disease is a common hemoglobinopathy seen in southern Chinese and Southeast Asian populations. It results from single amino acid replacement at 26th amino acid of the β chain (glutamic acid to lysine). Both heterozygous and homozygous individuals with HbE have mild hypochromic microcytic anemia. Combination of HbE and β thalassemia defects leads to HbE β thalassemia; it is seen exclusively in people of Southeast Asian descent. Clinical features of HbE β thalassemia resemble those of thalassemia intermedia.
Hemoglobin C disease
Hemoglobin C (HbC) disease is commonly seen in people of African descent. It is the second most common hemoglobinopathy in the U.S. It results from single amino acid substitution at the sixth 
BASICS OF NEWBORN SCREENING FOR HEMOGLOBINOPATHY
Isoelectric focusing (IEF) and highperformance liquid chromatography (HPLC) are the two common techniques used in the U.S. for detecting abnormal hemoglobinopathies. These methods have an excellent sensitivity and specificity for detecting abnormal hemoglobins. 16, 17 Generally, hemoglobin identified by neonatal screening is reported as a percentage. At birth, HbF is the more predominant than HbA. Hence, most normal infants show HbFA pattern. Even in most of the patients with hemoglobinopathies, HbF is still the predominant hemoglobin at birth.
On NBS, hemoglobin concentration is reported in decreasing order. For example, a report of "FAS" on NBS indicates that in the given sample the quantity of HbF is greater than that of HbA, and the quantity of HbA is greater than that of HbS.
Prior to interpretation of NBS, the following facts should be kept in mind.
1. Prematurity: The only hemoglobin that can be identified on NBS is HbF, because premature infants might still not have begun the hemoglobin switch from HbF to HbA. Therefore, hemoglobinopathies affecting HbA, such as SCD, HbC, and HbE, could potentially be missed. Hence, infants without HbA on their NBS should have a repeat NBS so that SCD and other hemoglobinopathies 3. Elevated Hb Bart's in NBS screen suggests an underlying defect in α chain.
4. Although NBS can help identify β thalassemia major, it is not a good screen for β thalassemia minor and β thalassemia intermedia. However, a follow-up screening and hematologic parameters such as mild anemia, microcytosis, and narrow red cell distribution width in high-risk groups could help identify this condition.
5. The most common abnormality detected in NBS is a carrier state for one of the hemoglobinopathies. In carrier states, the quantity (percentage) of normal adult hemoglobin is more than that of the abnormal variant, thus giving an "FAX" pattern, with X being the abnormal hemoglobin variant. For example, in SCT the NBS pattern would be FAS. Similarly in carriers of HbC and HbE, the patterns would be FAC and FAE, respectively.
ABNORMAL NBS PATTERNS
In most infants, FS pattern is due to clinically severe SCD (HbSS or HbSβ 0 thalassemia). Other possibilities include less severe phenotypes such as sickle δβ-thalassemia, and sickle hereditary persistence of fetal hemoglobin. 11 Not infrequently, newborns with HbSβ + thalassemia can also have an FS pattern at birth (Table 4) . However, a higher hemoglobin concentration and FSA pattern on re-testing at age 6 months could help in differentiating this from other severe phenotypes of SCD. 11 Identification of HbS with another hemoglobin variant such as HbC is not uncommon, and typically, the quantity of HbS is greater than the variant hemoglobin (eg, FSC in HbSC disease). The clinical and hematological characteristics of different sickle cell disease syndromes are highlighted in Table 2 . The coinheritance of α-thalassemia is common in SCD. In fact, approximately 30% of African Americans have one α gene defect, and approximately 2% have two α gene defects. 9 A characteristic FS pattern with elevated Hb Bart's can be seen in these newborns. Infants with positive NBS tests for SCD, confirmatory testing, and referral to a hematologist should be done by age 2 months so that parental education, prophylactic penicillin, and comprehensive care can be promptly implemented. Once an abnormal hemoglobinopathy screen result is reported to the PCP, the family should be informed and an appointment for follow-up should be made as soon as possible. Getting a baseline complete blood count with evaluation of peripheral smear and reticulocyte count could help in assessment of anemia and give valuable supportive information. On physical examination, attention should be given to presence or severity of pallor, jaundice, and hepatosplenomegaly. A repeat hemoglobin electrophoresis/HPLC testing to confirm the suspected hemoglobinopathy should be sent. After providing basic clinical information, referral to a hematologist and genetic counseling should be done. In certain situations, screening of family members (ie, complete blood count and hemoglobin electrophoresis) may provide rapid and valuable clinical information. When a carrier state is identified, education and genetic counseling should be offered to the family. The affected person should be informed of their carrier status in their adult life so that they are aware of potential risk of having an affected baby.
CONCLUSION
Early initiation of supportive care for infants with hemoglobinopathies such as sickle cell disease and thalassemia have been shown to decrease mortality and morbidity. Hence, accurate interpretation of newborn screening test for hemoglobinopathies/thalassemias is very important. This can be achieved by a basic understanding of hemoglobin structure and systematic approach in interpretation of results of newborn screening tests. Once hemoglobinopathy/thalassemia is suspected, patients should be referred to hematologists as appropriate.
